Ketamine for Treatment Resistant Depression

This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine’s psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine’s rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine’s rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research.

Produk Detail:

  • Author : Sanjay J. Mathew
  • Publisher : Springer
  • Pages : 155 pages
  • ISBN : 3319429256
  • Rating : 4/5 from 21 reviews
CLICK HERE TO GET THIS BOOKKetamine for Treatment Resistant Depression

Ketamine for Treatment-Resistant Depression

Ketamine for Treatment-Resistant Depression
  • Author : Sanjay J. Mathew,Carlos A. Zarate, Jr.
  • Publisher : Springer
  • Release : 25 November 2016
GET THIS BOOKKetamine for Treatment-Resistant Depression

This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant

Ketamine for Treatment-Resistant Depression

Ketamine for Treatment-Resistant Depression
  • Author : Gustavo H. Vazquez,Carlos A. Zarate,Elisa Brietzke
  • Publisher : Academic Press
  • Release : 01 October 2020
GET THIS BOOKKetamine for Treatment-Resistant Depression

Ketamine for Treatment-Resistant Depression: Neurobiology and Applications provides a simple, evidence-based overview for neuropsychiatrists and translational researchers on this medication, its mechanisms of actions, eligibility of patients for treatment, and the preparation and implementation of ketamine clinics. Provides efficacy research on ketamine as a treatment for depression Identifies best practices for clinical use, both long-term and acute Discusses the molecular mechanisms and neurobiology of action

Ketamine for Depression

Ketamine for Depression
  • Author : Dr. Stephen J. Hyde
  • Publisher : Xlibris Corporation
  • Release : 04 September 2015
GET THIS BOOKKetamine for Depression

Given the unacceptably high rates of suffering, disability and premature death experienced by people with treatment-resistant depression and the surprisingly low rates of problems arising from the use of ketamine to treat the disorder, this is a therapy that all patients and their doctors should be discussing. This book summarises the research that has been carried out into ketamine for the treatment of depression over the past 15 years and, most importantly, describes different ways of using ketamine that are both

Rapid Acting Antidepressants

Rapid Acting Antidepressants
  • Author : Anonim
  • Publisher : Academic Press
  • Release : 29 June 2020
GET THIS BOOKRapid Acting Antidepressants

The Advances in Pharmacology series presents a variety of chapters from the best authors in the field. Includes the authority and expertise of leading contributors in pharmacology Presents the latest release in the Advances in Pharmacology series

Treatment-resistant Mood Disorders

Treatment-resistant Mood Disorders
  • Author : Andre Carvalho,Roger McIntyre
  • Publisher : Oxford University Press, USA
  • Release : 01 May 2014
GET THIS BOOKTreatment-resistant Mood Disorders

Treatment-resistant major depression and bipolar disorder are highly prevalent and disabling conditions associated with substantial morbidity and mortality. The assessment and management of refractory patients with mood disorders is a major clinical challenge for mental health providers. Part of the Oxford Psychiatry Library (OPL) series, this pocketbook provides a concise view of the current definitions, assessment and evidence-based management of treatment-resistant mood disorders and reviews novel therapeutic targets for mood disorders, which may enhance the therapeutic armamentarium of clinicians in

11 - THE USE OF SUBCUTANEOUS KETAMINE FOR TREATMENT-RESISTANT DEPRESSION

11 - THE USE OF SUBCUTANEOUS KETAMINE FOR TREATMENT-RESISTANT DEPRESSION
  • Author : Mariane Quieroti Rodrigues
  • Publisher : Unknown Publisher
  • Release : 17 April 2021
GET THIS BOOK11 - THE USE OF SUBCUTANEOUS KETAMINE FOR TREATMENT-RESISTANT DEPRESSION

Introduction: Major depressive disorder is highly common with up to 50% to 60% of the patients not achieving adequate response following antidepressant treatment. In this scenario, ketamine emerges as an important alternative to conventional treatments, with its action of being an antagonist of N-methyl- D-aspartate (NMDA) receptor, once its has a quick and effective action. Ketamine is most frequently administered intravenous. However, oral, sublingual, transmucosal, intranasal, subcutaneous (SC), and intramuscular routes of administration have also been examined.Aim: This study aims to

Ketamine

Ketamine
  • Author : Kenji Hashimoto,Soichiro Ide,Kazutaka Ikeda
  • Publisher : Springer Nature
  • Release : 05 March 2020
GET THIS BOOKKetamine

This book presents the latest data from basic research and clinical trials supporting the effectiveness of ketamine as a treatment for depression, bipolar disorder, and suicidal behavior, setting these positive findings within the context of the serious problem of ketamine abuse. The first part of the book focuses on the evidence regarding ketamine abuse, with specific reference to Asian countries, and discusses countermeasures and complication management. It then addresses the mechanisms underlying the antidepressant and side effects of ketamine, which

The Ketamine Papers

The Ketamine Papers
  • Author : Kenneth Ring,Stanislav Grof,Ralph Metzner,Stanley Krippner,Eli Kolp,Harris Friedman,Evgeny Krupitsky,Karl Jansen,Mark Sylvester,M. Scott Young,Anna Kolp,Wesley Ryan,Cole Marta,Ralph Koek,Stephen Hyde,Steven Levine,Terrence Early,Jeffrey Becker
  • Publisher : Unknown Publisher
  • Release : 15 November 2016
GET THIS BOOKThe Ketamine Papers

The Ketamine Papers opens the door to a broad understanding of this medicine's growing use in psychiatry and its decades of history providing transformative personal experiences. Now gaining increasing recognition as a promising approach to the treatment of depression, posttraumatic stress disorder (PTSD), and other psychological conditions, ketamine therapies offer new hope for patients and clinicians alike. With multiple routes of administration and practices ranging from anesthesia to psychotherapy, ketamine medicine is a diverse and rapidly growing field. The Ketamine

Herbal Treatment of Major Depression: Scientific Basis and Practical Use

Herbal Treatment of Major Depression: Scientific Basis and Practical Use
  • Author : Scott D Mendelson
  • Publisher : CRC Press
  • Release : 27 November 2019
GET THIS BOOKHerbal Treatment of Major Depression: Scientific Basis and Practical Use

This unique volume presents new understandings of the neurochemical nature of major depression, and how herbs and their constituent flavonoids and terpenes appear to address some of the mechanisms now thought to be involved. It explores how recent studies of the rapid antidepressant effects of ketamine inform neuroscientists about deep intracellular mechanisms of antidepressant action that have little to do with simple enhancement of monoaminergic activity. These mechanisms include actions on PI3K, Akt, mTOR, GSK3, BDNF, and other intracellular

Pharmacotherapy of Depression

Pharmacotherapy of Depression
  • Author : Domenic A. Ciraulo,Richard Irwin Shader
  • Publisher : Springer Science & Business Media
  • Release : 28 December 2010
GET THIS BOOKPharmacotherapy of Depression

Comprehensive and state of the art, the second edition of Pharmacotherapy of Depression offers major revisions of every chapter and the addition of new chapters by expert contributors. The first chapter reviews the neurobiology of depression, which lays the groundwork for understanding the mechanisms of action of antidepressants. In the next chapter, a review of the general principles guiding the diagnosis and medication treatment of unipolar depression is provided. The clinical pharmacology of antidepressants is reviewed in some detail, supplemented

Bipolar, Not So Much: Understanding Your Mood Swings and Depression

Bipolar, Not So Much: Understanding Your Mood Swings and Depression
  • Author : Chris Aiken,James Phelps
  • Publisher : W. W. Norton & Company
  • Release : 17 January 2017
GET THIS BOOKBipolar, Not So Much: Understanding Your Mood Swings and Depression

Approaching depression as a complex disorder with many different facets rather than all-or-nothing. Depression confuses the mind, strips away hope, and causes people to blame themselves for an illness they never asked for. This book presents a revolutionary new understanding of the concept of depression and offers readers skills and strategies to manage it. No longer is this a one-size-fits-all diagnosis, and antidepressants are no longer the one-size-fits-all treatment. Mood disorders are now seen to form a spectrum of problems,

Repeated Intranasal Ketamine for Treatment-resistant Depression – the Way to Go? Results from a Pilot Randomised Controlled Trial

Repeated Intranasal Ketamine for Treatment-resistant Depression – the Way to Go? Results from a Pilot Randomised Controlled Trial
  • Author : Anonim
  • Publisher : Unknown Publisher
  • Release : 17 April 2021
GET THIS BOOKRepeated Intranasal Ketamine for Treatment-resistant Depression – the Way to Go? Results from a Pilot Randomised Controlled Trial

Background: Ketamine research in depression has mostly used intravenous, weight-based approaches, which are difficult to translate clinically. Intranasal (IN) ketamine is a promising alternative but no controlled data has been published on the feasibility, safety and potential efficacy of repeated IN ketamine treatments. Methods: This randomised, double-blind, placebo-controlled pilot study compared a 4-week course of eight treatments of 100 mg ketamine or 4.5 mg midazolam. Each treatment was given as 10 separate IN sprays, self-administered 5 min apart. The study was stopped early due

Depression: From Psychopathology to Pharmacotherapy

Depression: From Psychopathology to Pharmacotherapy
  • Author : J.F. Cryan,B.E. Leonard
  • Publisher : Karger Medical and Scientific Publishers
  • Release : 17 November 2010
GET THIS BOOKDepression: From Psychopathology to Pharmacotherapy

Despite the availability of antidepressants for over 40 years, a substantial proportion of depressed patients do not respond adequately to treatment. Failure to respond effectively to treatment contributes to physical ill-health and psychiatric morbidity, often resulting in premature death of the depressed patient. The purpose of this volume is to consider the possible reasons for the limitations of the currently available antidepressants, to examine the advances in our understanding of the psychopathology of depression and how such knowledge may assist in

Cognition in Major Depressive Disorder

Cognition in Major Depressive Disorder
  • Author : Roger S. McIntyre,Danielle S. Cha,Joanna K. Soczynska
  • Publisher : OUP Oxford
  • Release : 08 May 2014
GET THIS BOOKCognition in Major Depressive Disorder

Part of the Oxford Psychiatry Library (OPL) series, Cognition in Major Depressive Disorder provides a succinct summary of cognitive deficits reported in patients with major depressive disorder (MDD) with a particular focus on aspects of measurement, underlying disease pathophysiology, implications for treatment and prevention. This book also provides readers an opportunity for clinical-based assessment of cognition and recommendations for how cognitive measurement and treatment is positioned in the management of individuals with mood disorders.